Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage

Ocugen, Inc. (NASDAQ:OCGN) on Thursday shared preliminary data from its phase 2 clinical trial for OCU410, a gene therapy targeting geographic atrophy. • Ocugen stock is taking a hit today. What’s weighing on OCGN shares?The stock’s decline comes as the broader market is experiencing gains, with major indices such as the S&P 500 up 0.64% and the Nasdaq gaining 1.07%.Ocugen’s Phase 2 Trial Shows 46% Lesion ReductionPreliminary results from the Phase 2 ArMaDa clinical trial indicate a 46% reduction in lesion ...